Abstract: The present disclosure relates to a neutralising epitope for Tenascin-C, and binding domains specific thereto, for example antibodies or binding fragments thereof, pharmaceutical compositions comprising the same and use of said antibodies, binding fragments or composition in treatment, in particular the treatment of an inflammatory disorder.

Abstract: The invention relates to a method of identifying a subject suspected of having or being susceptible to an autoimmune disease, such as rheumatoid arthritis (RA), comprising: contacting a sample of bodily fluid obtained from the subject with (i) a binding pair member having a binding affinity for citrullinated tenascin (cTNC) or a fragment thereof or (ii) a cTNC peptide; determining in a sample of bodily fluid obtained from the subject the presence or amount of (i) a citrullinated peptide derived from tenascin or (ii) an anti cTNC antibody; comparing the presence or amount of (i) the citrullinated peptide derived from tenascin or (ii) the anti cTNC antibody with a pre-defined threshold value; and assigning a diagnosis of RA or a future likelihood of developing RA when the presence or amount of (i) cTNC or (ii) an antibody against cTNC is detected or exceeds the threshold; and associated kits, peptides, binding members and uses thereof.